<DOC>
	<DOCNO>NCT00987636</DOCNO>
	<brief_summary>Ewing Sarcoma Primary objective : Standard Risk R1 : randomised trial , examine whether add-on treatment zoledronic acid addition induction maintenance chemotherapy improve event-free survival patient localise Ewing sarcoma good histological response initial tumour volume &lt; 200 mL compare add-on treatment . *High Risk R2 : randomised trial , examine whether high-dose chemotherapy use busulfan-melphalan autologous stem cell reinfusion , compare standard chemotherapy , improve event-free survival patient localise Ewing sarcoma poor histological response tumour volume ≥200 mL ( R2loc ) . In patient pulmonary metastasis high dose busulfan-melphalan chemotherapy autologous stem cell reinfusion randomise versus standard chemotherapy plus whole lung irradiation ( R2pulm ) . Very High Risk R3 : randomised trial , examine whether addition high dose chemotherapy use treosulfan-melphalan follow autologous stem cell reinfusion eight cycle standard adjuvant chemotherapy , compare eight cycle standard adjuvant chemotherapy alone , improve event-free survival patient primary disseminated disease . *R2 accrual discontinue December 1st 2015 .</brief_summary>
	<brief_title>Study Localized Disseminated Ewing Sarcoma</brief_title>
	<detailed_description>EWING 2008 joint protocol European North American Ewing sarcoma study group . The protocol aim optimise treatment treatment result patient Ewing sarcoma . The EWING 2008 protocol open patient diagnose Ewing sarcoma , localise metastatic , consider eligible neoadjuvant chemotherapy . All patient register receive induction chemotherapy consist six cycle vincristine , ifosfamide , doxorubicin etoposide ( VIDE ) . The decision regard local therapy must make follow fifth cycle induction treatment , preference surgical intervention without additional radiotherapy . Preoperative radiotherapy may consider improve operability otherwise inoperable lesion . In patient localised disease pulmonary metastasis , local treatment perform follow 6th cycle VIDE chemotherapy , complete tumour resection , whenever feasible . Post-operative radiotherapy determine completeness surgery histological response chemotherapy . Standard Risk R1 Good responder ( R1 ) ( &lt; 10 % viable tumour cell ) localise disease allocate standard risk arm receive eight cycle chemotherapy compose vincristine , actinomycin D , cyclophosphamide ( VAC ) ( female ) ifosfamide instead cyclophosphamide ( VAI ) ( male ) . They randomise receive add-on treatment either fenretinide , zoledronic acid , fenretinide plus zoledronic acid , add-on treatment . High Risk R2 *Poor responder ( R2 ) localise disease continue randomise EURO-E.W.I.N.G . 99 receive either eight cycle VAI chemotherapy high dose treatment busulfan-melphalan ( R2loc ) . Patients primary pulmonary metastasis also allocate continue randomise EURO-E.W.I.N.G . 99 receive either eight cycle VAI chemotherapy high dose treatment busulfan-melphalan ( R2pulm ) . Very High Risk R3 Patients disseminate disease , i.e . dissemination bone and/or sit possibly additional pulmonary dissemination ( R3 ) , receive six cycle VIDE induction chemotherapy . Patients randomise either continue eight cycle vincristine , actinomycin D cyclophosphamide ( VAC ) chemotherapy high dose treosulfan-melphalan ( TreoMel ) chemotherapy follow autologous stem cell reinfusion follow thereafter eight cycle VAC chemotherapy . Local therapy R3 patient follow VIDE induction , whenever feasible prior high dose therapy ( HDT ) . When long period immobilisation follow surgery anticipate , e.g pelvic reconstruction , surgery follow HDT may advisable . Depending clinical response induction chemotherapy radiotherapy prior HDT surgery may option consider patient . Any delay VIDE HDT reason e.g . local treatment must bridge VAC cycle . The total number VAC cycle exceed eight cycle . *R2 accrual discontinue December 1st 2015 .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Diagnosis : Histologically confirm Ewing sarcoma bone soft tissue . Age sex : Either sex , age &gt; 48 month ( GPOH patient ) &lt; 50 year date diagnostic biopsy . Younger elderly patient may report appropriate office ( see section 1.4 ) include study . Registration : ≤ 45 day diagnostic biopsy/surgery . Start chemotherapy : ≤ 45 day diagnostic biopsy/surgery . Informed consent : Must sign prior study entry . Performance status : Lansky Karnofsky score &gt; 50 % , may modify handicapped patient . Haematological parameter : Haemoglobin &gt; 8 g/dl ( transfusion allow ) , Platelets &gt; 80.000/µl ( transfusion allow ) , WBC &gt; 2000/µl . Cardiac value : LVEF &gt; 40 % , SF &gt; 28 % . More one cycle chemotherapy prior registration Second malignancy Pregnancy lactation Concurrent treatment within clinical trial , except trial different endpoint due nature endpoint must run parallel EWING 2008 e.g . trial antiemetic , antimycotic , antibiotic , strategy psychosocial support , etc ... Any medical , psychiatric , social condition incompatible protocol treatment</criteria>
	<gender>All</gender>
	<minimum_age>48 Months</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Ewing Sarcoma</keyword>
	<keyword>localize</keyword>
	<keyword>disseminate</keyword>
	<keyword>metastasis</keyword>
	<keyword>bone</keyword>
	<keyword>soft tissue</keyword>
</DOC>